1997 revised guidelines for performing CD4+ T-cell determinations in persons infected with human immunodeficiency virus (HIV) by Centers for Disease Control and Prevention (U.S.)




U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Centers for Disease Control
and Prevention (CDC)
Atlanta, Georgia 30333
1997 Revised Guidelines for
Performing CD4+ T-Cell Determinations
in Persons Infected with
Human Immunodeficiency Virus (HIV)
TM
The MMWR series of publications is published by the Epidemiology Program Office,
Centers for Disease Control and Prevention (CDC), Public Health Service, U.S. Depart-
ment of Health and Human Services, Atlanta, GA 30333.
Centers for Disease Control and Prevention.......................... David Satcher, M.D., Ph.D.
Director 
The material in this report was prepared for publication by:
 National Center for Infectious Diseases.................................. James M. Hughes, M.D.
Director 
  Division of AIDS, STD, and TB Laboratory Research..............Harold W. Jaffe, M.D.
Director 
 Public Health Practice Program Office ........................................Edward L. Baker, M.D.
Director 
  Division of Laboratory Systems..................................Carlyn L. Collins, M.D., M.P.H.
Director 
The production of this report as an MMWR serial publication was coordinated in:
 Epidemiology Program Office.................................... Stephen B. Thacker, M.D., M.Sc.
Director 
Richard A. Goodman, M.D., M.P.H.
Editor, MMWR Series 
  Office of Scientific and Health Communications (proposed)




  Morie M. Higgins
Peter M. Jenkins
Visual Information Specialists 
SUGGESTED CITATION
Centers for Disease Control and Prevention. 1997 Revised guidelines for perform-
ing CD4+ T-cell determinations in persons infected with human immuno-
deficiency virus (HIV). MMWR 1997;46(No. RR-2):[inclusive page numbers].
Copies can be purchased from Superintendent of Documents, U.S. Government
Printing Office, Washington, DC 20402-9325. Telephone: (202) 512-1800.
Use of trade names and commercial sources is for identification only and does not









Single copies of this document are available from the Centers for Disease Control
and Prevention, National AIDS Clearinghouse, P.O. Box 6003, Rockville, MD 20850.
Telephone: (800) 458-5231.
Vol. 46 / No. RR-2 MMWR i
The following CDC staff members prepared this report:
Janet K.A. Nicholson, Ph.D.
Division of AIDS, STD, and TB Laboratory Research
National Center for Infectious Diseases
Thomas L. Hearn, Ph.D.
G. David Cross, M.S.
Mark D. White
Division of Laboratory Systems
Public Health Practice Program Office
ii MMWR January 10, 1997
1997 Revised Guidelines for Performing
CD4+ T-Cell Determinations in Persons Infected
 with Human Immunodeficiency Virus (HIV)
Summary
These revised guidelines were developed by CDC for laboratories performing
lymphocyte immunophenotyping assays in human immunodeficiency virus-
infected persons. This report updates previous recommendations (MMWR
43[No. RR-3]) and reflects current technology in a field that is rapidly changing.
The recommendations address laboratory safety, specimen collection, speci-
men transport, maintenance of specimen integrity, specimen processing, flow
cytometer quality control, sample analyses, data analysis, data storage, data re-
porting, and quality assurance.
INTRODUCTION
Accurate and reliable measures of CD4+ T-lymphocytes (CD4+ T-cells) are essential
to the assessment of the immune system of human immunodeficiency virus (HIV)-
infected persons (1–3 ). The pathogenesis of acquired immunodeficiency syndrome
(AIDS) is largely attributable to the decrease in T-lymphocytes that bear the CD4 recep-
tor (4–8 ). Progressive depletion of CD4+ T-lymphocytes is associated with an
increased likelihood of clinical complications (9,10 ). Consequently, the Public Health
Service (PHS) has recommended that CD4+ T-lymphocyte levels be monitored every
3–6 months in all HIV-infected persons (11 ). The measurement of CD4+ T-cell levels
has been used to establish decision points for initiating Pneumocystis carinii  pneu-
monia prophylaxis (12 ) and antiviral therapy (13 ) and to monitor the efficacy of
treatment (14–16 ). CD4+ T-lymphocyte levels also are used as prognostic indicators in
patients who have HIV disease (17,18 ) and recently have been included as one of the
criteria for initiating prophylaxis for several opportunistic infections that are sequelae
of HIV infection (19,20 ). Moreover, CD4+ T-lymphocyte levels are a criterion for cate-
gorizing HIV-related clinical conditions by CDC’s classification system for HIV infection
and surveillance case definition for AIDS among adults and adolescents (21 ).
Most laboratories measure absolute CD4+ T-cell levels in whole blood by a multi-
platform, three-stage process. The CD4+ T-cell number is the product of three
laboratory techniques: the white blood cell (WBC) count; the percentage of WBCs
that are lymphocytes (differential); and the percentage of lymphocytes that are
CD4+ T-cells. The last stage in the process of measuring the percentage of CD4+ T-
lymphocytes in the whole-blood sample is referred to as “immunophenotyping by
flow cytometry” (22–28 ). Immunophenotyping refers to the detection of antigenic de-
terminants (which are unique to particular cell types) on the surface of WBCs using
antigen-specific monoclonal antibodies that have been labeled with a fluorescent dye
or fluorochrome (e.g., phycoerythrin [PE] or fluorescein isothiocyanate [FITC]). The
fluorochrome-labeled cells are analyzed by using a flow cytometer, which categorizes
individual cells according to size, granularity, fluorochrome, and intensity of fluores-
cence. Size and granularity, detected by light scattering, characterize the types of
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WBCs (i.e., granulocytes, monocytes, and lymphocytes). Fluorochrome-labeled anti-
bodies distinguish populations and subpopulations of WBCs. Although flow cyto-
metric immunophenotyping is a highly complex technology, methodology for per-
forming CD4+ T-cell determinations has become more standardized between
laboratories. The publication of several sets of guidelines addressing aspects of the
CD4+ T-lymphocyte testing process (e.g., quality control, quality assurance, and re-
agents for flow cytometric immunophenotyping of lymphocytes) has contributed to
this standardization (29–32 ).
The CDC guidelines concerning CD4+ T-cell determinations (33 ) were first publish-
ed in the MMWR in 1992 to provide laboratorians with the most complete information
about how to measure CD4+ T-lymphocytes in blood from HIV-infected persons by
using flow cytometry. These guidelines were based on data from scientific literature,
information from discussions with technical experts, and experience with related vol-
untary standards for flow cytometric analyses (29 ). The 1992 guidelines concluded
that more data were needed and that revisions would be published as additional infor-
mation became available and as important innovations in technology were made. In
1993, a national conference was convened by CDC with sponsorship from the Food
and Drug Administration (FDA), National Institutes of Health, and Association of State
and Territorial Public Health Laboratory Directors. The objectives of the conference
were to review data collected after 1992 and to obtain input about the efficacy of the
1992 guidelines. As a result of the 1993 conference, the revised guidelines for perform-
ing CD4+ T-cell determinations in HIV-infected persons were published in 1994 (34 ).
Since 1994, the field of CD4+ T-cell testing has rapidly expanded. Flow cytometric
analyses of T-cell subsets using three- and four-color approaches (in contrast to the
two-color approach addressed in previous reports [35,36 ]), flow cytometric analyses
for measuring both the proportion and the absolute numbers of CD4+ T-lymphocytes,
and other methods for deriving an absolute CD4+ T-cell count in a blood sample are
now commercially available. (Some of these other methods do not depend on the
multi-stage process and are collectively referred to in this report as single-platform
methods.) Moreover, data evaluating some of the parameters of two-color flow cy-
tometric testing and the routine testing practices of laboratories that provide these
testing services have been collected. A second national conference on CD4+ T-
lymphocyte immunophenotyping was held in Atlanta, Georgia, on December 12–13,
1995, to discuss these changes. Information shared at the conference and new data
collected about laboratory testing practices serve as the basis for the revisions and
additions that have been made to the 1994 guidelines. These changes include a) qual-
ity assurance (namely, revision of the recommended monoclonal panel to provide a
cost-effective solution for laboratories using three-color and four-color approaches),
b) the importance of following manufacturers’ instructions when using tests and test-
ing devices approved by the FDA, c) recommendations for laboratories performing
three- and four-color T-lymphocyte immunophenotyping (TLI), and d) recommenda-
tions about the validation and verification procedures that laboratories should
conduct before implementing new tests.
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RECOMMENDATIONS
I. Laboratory Safety
A. Use universal precautions with all specimens (37 ).
B. Establish the following safety practices (38–44 ):
 1. Wear laboratory coats and gloves when processing and analyzing speci-
mens, including reading specimens on the flow cytometer.
 2. Never pipette by mouth. Use safety pipetting devices.
 3. Never recap needles. Dispose of needles and syringes in puncture-proof
containers designed for this purpose.
 4. Handle and manipulate specimens (e.g., aliquoting, adding reagents,
vortexing, and aspirating) in a class I or II biological safety cabinet.
 5. Centrifuge specimens in safety carriers.
 6. After working with specimens, remove gloves and wash hands with
soap and water.
 7. For stream-in-air flow cytometers, follow the manufacturer’s recom-
mended procedures to eliminate the operator’s exposure to any aerosols
or droplets of sample material.
 8. Disinfect flow cytometer wastes. Add a volume of undiluted household
bleach (5% sodium hypochlorite) to the waste container before adding
waste materials so that the final concentration of bleach will be 10%
(0.5% sodium hypochlorite) when the container is full (e.g., add 100 mL
of undiluted bleach to an empty 1,000-mL container).
 9. Disinfect the flow cytometer as recommended by the manufacturer. One
method is to flush the flow cytometer fluidics with a 10% bleach solution
for 5–10 minutes at the end of the day, then flush with water or saline for
at least 10 minutes to remove excess bleach, which is corrosive.
10. Disinfect spills with household bleach or an appropriate dilution of my-
cobactericidal disinfectant. Note: Organic matter will reduce the ability
of bleach to disinfect infectious agents. For specific procedures about
how areas should be disinfected, see reference 44. For use on smooth,
hard surfaces, a 1% solution of bleach is usually adequate for disinfec-
tion; for porous surfaces, a 10% solution is needed (44 ).
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11. Assure that all samples have been properly fixed after staining and lys-
ing, but before analysis. Note: Some commercial lysing/fixing reagents
will reduce the infectious activity of cell-associated HIV by 3–5 logs (45 );
however, these reagents have not been evaluated for their effectiveness
against other agents (e.g., hepatitis virus). Buffered (pH 7.0–7.4) 1%–
2% paraformaldehyde or formaldehyde can inactivate cell-associated
HIV to approximately the same extent (45–48 ). Cell-free HIV can be inac-
tivated with 1% paraformaldehyde within 30 minutes (49 ). Because the
commercial lysing/fixing reagents do not completely inactivate cell-
associated HIV and the time frame for complete inactivation is not firmly
established, stained and lysed samples should be resuspended and re-
tained in fresh 1%–2% paraformaldehyde or formaldehyde through flow
cytometric analysis.
II. Specimen Collection
A. Select the appropriate anticoagulant for hematologic testing and flow cy-
tometric immunophenotyping.
1. Anticoagulant for hematologic testing:
a. Use tripotassium ethylenediamine tetra-acetate (K3EDTA, 1.5 ±
0.15 mg/mL blood) (50,51 ), and perform the test within the time frame
allowed by the manufacturer of the hematology analyzer, not to ex-
ceed 30 hours.
b. Reject a specimen that cannot be processed within this time frame
unless the hematology instrumentation is suitable for analyzing such
specimens. Note: Some hematology instruments are capable of gen-
erating accurate results 12–30 hours after specimen collection (52 ). To
ensure accurate results for specimens from HIV-infected persons,
laboratories must validate their hematology instrument’s ability to
give the same result at time 0 and at the maximum time claimed by
the manufacturer when using specimens from both persons infected
with HIV and those not infected.
2. Anticoagulant for flow cytometric immunophenotyping, depending on
the delay anticipated before sample processing:
a. Use K3EDTA, acid citrate dextrose (ACD), or heparin if specimens will
be processed within 30 hours after collection. Note: K3EDTA should
not be used for specimens held for >30 hours before testing because
the proportion of some lymphocyte populations changes after this
period (53 ).
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b. Use either ACD or heparin, not K3EDTA, if specimens will be processed
within 48 hours after specimen collection.
c. Reject a specimen that cannot be processed within 48 hours after
specimen collection and request another.
B. Collect blood specimens by venipuncture (54 ) into evacuated tubes con-
taining an appropriate anticoagulant, completely expending the vacuum in
the tubes.
1. Draw specimens from children in pediatric tubes to avoid underdrawing.
2. Mix the blood well with the anticoagulant to prevent clotting.
C. Draw the appropriate number of tubes:
1. Use one tube containing K3EDTA when a) hematology and flow cytomet-
ric immunophenotyping will be performed in the same laboratory on the
same specimen or b) a single measurement is performed on the flow
cytometer that results in an absolute number. Note: For single-platform
methods that do not use determinations from a hematology analyzer or
from conventional flow cytometers to derive absolute CD4+ T-cell num-
bers, follow the manufacturer’s recommendations for anticoagulant and
maximum times between specimen collection and testing.
2. In all other circumstances, draw two separate tubes (K3EDTA for hema-
tologic determinations and K3EDTA, ACD, or heparin for flow cytometric
immunophenotyping).
D. Label all specimens with the date, time of collection, and a unique patient
identifier.
1. Assure that patient information and test results are accorded
confidentiality.
2. Provide on the submission form pertinent medications and disease con-
ditions that may affect the immunophenotyping test (Appendix).
III. Specimen Transport
A. Maintain and transport specimens at room temperature (64–72 F [18–22 C])
(52,55–57 ). Avoid extremes in temperature so that specimens do not freeze
or become too hot. Temperatures >99 F (37 C) may cause cellular destruc-
tion and affect both hematology and flow cytometry measurements (52 ).
In hot weather, packing the specimen in an insulated container and placing
this container inside another containing an ice pack and absorbent mate-
rial may be necessary. This method helps retain the specimen at ambient
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temperature. The effect of cool temperatures (i.e., 39 F [4 C]) on
immunophenotyping results is not clear (52,57 ).
B. Transport specimens to the immunophenotyping laboratory as soon as
possible.
C. For transport to locations outside the collection facility but within the state,
follow state or local guidelines. One method for packaging such specimens
is to place the tube containing the specimen in a leak-proof container (e.g.,
a sealed plastic bag) and to pack this container inside a cardboard canister
containing sufficient material to absorb all the blood should the tube break
or leak. Cap the canister tightly. Fasten the request slip securely to the out-
side of this canister with a rubber band. For mailing, this canister should be
placed inside another canister containing the mailing label.
D. For interstate shipment, follow federal guidelines* for transporting diagnos-
tic specimens. Note: Use overnight carriers with an established record of
consistent overnight delivery to ensure arrival the following day. Check with
these carriers for their specific packaging requirements.
E. Obtain specific protocols and arrange appropriate times of collection and
transport from the facility collecting the specimen.
IV. Specimen Integrity
A. Inspect the tube and its contents immediately upon arrival.
B. Take corrective actions if the following occur:
1. If the specimen is hot or cold to the touch but not obviously hemolyzed
or frozen, process it but note the temperature condition on the work-
sheet and report form. Do not rapidly warm or chill specimens to bring
them to room temperature because this may adversely affect the immu-
nophenotyping results (52 ). Abnormalities in light-scattering patterns
will reveal a compromised specimen.
2. If blood is hemolyzed or frozen, reject the specimen and request another.
3. If clots are visible, reject the specimen and request another.




*49 CFR parts 100–171 (56 FR 47158).
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1. Perform the hematologic tests within the time frame specified by the
manufacturer of the specific hematology instrument used (time from
blood specimen draw to hematologic test). (See Note under II.A.1.b.)
2. Perform an automated WBC count and differential, counting 10,000–
30,000 cells (58 ). If the specimen is rejected or “flagged” by the instru-
ment, a manual differential of at least 400 cells can be performed. If the
flag is not on the lymphocyte population and the lymphocyte differential
is reported by the instrument, the automated lymphocyte differential
should be used.
3. If absolute counts are determined by using a single-platform method,
hematology results are not needed for this determination.
B. Immunophenotyping
1. For optimal results, perform the test within 30 hours, but no later than
48 hours, after drawing the blood specimen (59,60 ).
2. When centrifuging, maintain centrifugation forces of no greater than
400 g for 3–5 minutes for wash steps.
3. Vortex sample tubes to mix the blood and reagents and break up cell
aggregates. Vortex samples immediately before analysis to optimally
disperse cells.
4. Include a source of protein (e.g., fetal bovine serum or bovine serum
albumin) in the wash buffer to reduce cell clumps and non-specific
fluorescence.
5. Incubate all tubes in the dark during the immunophenotyping procedure.
6. Before analysis on the flow cytometer, be sure all samples have been
adequately fixed. Although some of the commercial lysing/fixing re-
agents can inactivate cell-associated HIV, all tubes should be fixed after
staining and lysing with 1%–2% buffered paraformaldehyde or formalde-
hyde. Note: The characteristics of paraformaldehyde and formaldehyde
may vary between lots. They may also lose their effectiveness over time.
Therefore, these fixatives should be made fresh weekly from electron-
microscopy–grade aqueous stock.
7. Immediately after processing the specimens, store all stained samples in
the dark and at refrigerator temperatures (39–50 F [4–10 C]) until flow
cytometric analysis. These specimens should be stored for no longer
than 24 hours unless the laboratory can demonstrate that scatter and
fluorescence patterns do not change for specimens stored longer.
8. If absolute counts are determined on the flow cytometer, follow the
manufacturer’s recommended protocols.
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VI. Monoclonal Antibody Panels
A. Monoclonal antibody panels must contain appropriate monoclonal anti-
body combinations to enumerate CD4+ and CD8+ T-cells and to ensure the
quality of the results (61 ).
1. CD4 T-cells must be identified as being positive for both CD3 and CD4.
2. CD8 T-cells must be identified as being positive for both CD3 and CD8.
B. Two-color monoclonal antibody panels
1. The recommended two-color immunophenotyping antibody panel
(Table 1), delineated by CD nomenclature (62 ) and fluorochrome, pro-
vides data useful for defining the T-cell population and subpopulations;
determining the recovery and purity of the lymphocytes in the gate; set-
ting cursors for positivity; accounting for all lymphocytes in the sample;
monitoring tube-to-tube variability; and monitoring T-cell, B-cell, and
natural killer (NK)-cell levels. The following internal controls are included
in the panel:
a. CD3 Monoclonal antibody in tubes 3–6 serves as a control for tube-to-
tube variability and is also used to determine T-cell populations.
Note: All CD3 values in this six-tube panel should be within 3% of each
other. If the CD3 value of a tube is >3% of any of the others, that tube
should be repeated (i.e., new aliquot of blood labeled, lysed, and
fixed).
b. Monoclonal antibodies that label T-cells, B-cells, and NK-cells are used
to account for all lymphocytes in the specimen (61 ).





    Phycoerythrin
      (PE)  
Cell populations
identified
1 CD45     CD14 Lymphocytes,
monocytes,
and granulocytes
2 Isotype     Isotype —
3 CD3     CD4 CD4+ T-cells
4 CD3     CD8 CD8+ T-cells
5 CD3     CD19 T-cells, B-cells
6 CD3     CD16 and/or CD56 T-cells, NK-cells
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2. An abbreviated two-color panel should only be used for testing speci-
mens from patients for whom CD4+ T-cell levels are being requested as
part of sequential follow-up, and then only after consulting with the re-
questing clinician. Because some of the internal controls are no longer
included, when using an abbreviated panel, the immunophenotyping
results should be reviewed carefully to ensure that CD3+ T-cell levels are
similar to those determined previously with the full recommended
panel. When discrepancies occur, the specimens must be reprocessed
by using the full recommended two-color monoclonal antibody panel.
C. Three-color monoclonal antibody panels
1. Three-color monoclonal antibody panels should fulfill the following
basic requirements: enumerate CD4+ and CD8+ T-cells, validate the
lymphocyte gate used, and provide some assessment of tube-to-tube
variability.
2. For determining T-cell subset percentages, the third color should be used
to identify lymphocytes by following one of two procedures (Table 2):
a. Use CD45 as the third color to identify lymphocytes as those cells that
are bright CD45+ but have low side scattering properties. In this case,
the panel would consist of the following monoclonal antibodies:
CD3/CD4/CD45; CD3/CD8/CD45; and CD3/CD19/CD45 (Table 2,
Panel A).
b. Use lineage markers (T-cell, B-cell, and NK-cell) to identify lympho-
cytes (63 ). The panel would consist of the following monoclonal
TABLE 2. Three-color monoclonal antibody panels*
Panel Monoclonal antibodies Notes
A CD3/CD4/CD45 Gate on CD45 and side scatter; measure CD3+CD4+
T-cells
CD3/CD8/CD45 Gate on CD45 and side scatter; measure CD3+CD8+
T-cells
CD3/CD19/CD45† Gate on CD45 and side scatter; measure CD3+ and
CD19+ T-cells
B§ CD3/CD19/CD16 and/or CD56 For absolute counts of T-, B-, and NK-cells
CD3/CD4/CD8 To determine CD3+, CD3+CD4+, and CD3+CD8+ cells
Isotype control For nonspecific fluorescence
*Suggested three-color panels. (See Section VI.C.)
†Recommended for specimens obtained from children (32).
§This panel may be used for systems determining absolute cell numbers directly from the flow
cytometer. Percentage determinations are calculated from the absolute numbers. (See Section
VI.C.2.b.)
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antibodies: CD3/CD19/CD16 and/or CD56; CD3/CD4/CD8; and an iso-
type control (Table 2, Panel B). Note: Software on the flow cytometer
must be capable of using the information obtained from these mono-
clonal antibody combinations to correctly identify lymphocytes and to
extrapolate that information to determine the percentage of lympho-
cytes that are CD4+ and CD8+ T-cells (63 ). Note: A single tube
containing CD3, CD4, and CD8 monoclonal antibodies is not appropri-
ate for determining the percentage of lymphocytes that are CD4+ or
CD8+ T-cells because there is no method to validate the lymphocyte
gate in this tube without the addition of another tube for that purpose.
Lymphocyte gate purity and recovery cannot be determined. Internal
quality control measures may be obtained by adding another tube
containing CD3 (e.g., CD3, CD19, and CD16 and/or CD56).
3. A three-color monoclonal antibody panel must consist of at least two
tubes, each with the same lineage marker. For the examples above, CD3
is the common lineage marker in each tube. Differences between repli-
cate CD3 results should be ≤2%. Note: The variability of a CD3 result
between two tubes is approximately half that of four tubes.
D. Four-color monoclonal antibody panels
1. Addition of CD45 to a single tube containing CD3, CD4, and CD8 allows
the identification of lymphocytes based on CD45 and side scatter and the
enumeration of CD4+ and CD8+ T-lymphocytes.
2. A four-color monoclonal antibody panel must consist of at least two
tubes, each with the same lineage marker. A second tube containing
CD45, CD3, CD19, and CD16 and/or CD56 is recommended.
VII. Negative and Positive Controls for Immunophenotyping
A. Negative (isotype) reagent control
1. Use this control to determine nonspecific binding of the mouse mono-
clonal antibody to the cells and to set markers for distinguishing
fluorescence-negative and fluorescence-positive cell populations.
2. Use a monoclonal antibody with no specificity for human blood cells but
of the same isotype(s) as the test reagents. Note: In many cases, the iso-
type control may not be optimal for controlling nonspecific fluorescence
because of differences in F/P ratio, antibody concentration between the
isotype control and the test reagents, and other characteristics of the im-
munoglobulin in the isotype control. Additionally, isotype control
reagents from one manufacturer are not appropriate for use with test
reagents from another manufacturer.
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3. The isotype control is not needed for use with CD45 because CD45 is
used to identify leukocyte populations based on fluorescence intensity.
4. For monoclonal antibody panels containing antibodies to CD3, CD4, and
CD8, the isotype control may not be needed because labeling with these
antibodies results in fluorescence patterns in which the unlabeled cells
are clearly separated from the labeled cells. In these instances, the nega-
tive cells in the histogram are the appropriate isotype control.
5. The isotype control must be used when a monoclonal antibody panel
contains monoclonal antibodies that label populations that do not have
a distinct negative population (e.g., some CD16 or CD56 monoclonal
antibodies).
B. Positive methodologic control
1. The methodologic control is used to determine whether procedures for
preparing and processing the specimens are optimal. This control is pre-
pared each time specimens from patients are prepared.
2. Use either a whole-blood specimen from a control donor or commercial
materials validated for this purpose. Ideally, this control will match the
population of patients tested in the laboratory. (See Section XII.D.)
3. If the methodologic control falls outside established normal ranges, de-
termine the reason. Note: The purpose of the methodologic control is to
detect problems in preparing and processing the specimens. Biologic
factors that cause only the whole-blood methodologic control to fall out-
side normal ranges do not invalidate the results from other specimens
processed at the same time. Poor lysis or poor labeling in all specimens,
including the methodologic control, invalidates results.
C. Positive control for testing reagents
1. Use this control to test the labeling efficiency of new lots of reagents or
when the labeling efficiency of the current lot is questioned. Prepare this
control only when needed (i.e., when reagents are in question) in parallel
with lots of reagents of known acceptable performance. Note: New re-
agents must demonstrate similar results to those of known acceptable
performance.
2. Use a whole-blood specimen or other human lymphocyte preparation
(e.g., cryopreserved or commercially obtained lyophilized lymphocytes).
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VIII.Flow Cytometer Quality Control (29 )
A. Align optics daily. This ensures that the brightest and tightest peaks are pro-
duced in all parameters. Note: Some clinical flow cytometers can be aligned
by laboratory personnel whereas others can be aligned only by qualified
service personnel.
1. Align the flow cytometer by using stable calibration material (e.g., mi-
crobeads labeled with fluorochromes) that has measurable forward
scatter, side scatter, and fluorescence peaks.
2. Align the calibration particles optimally in the path of the laser beam and
in relation to the collection lens so the brightest and tightest peaks are
obtained.
3. Align stream-in-air flow cytometers daily (at a minimum) and stream-in-
cuvette flow cytometers (most clinical flow cytometers are this type) as
recommended by the manufacturer.
B. Standardize daily. This ensures that the flow cytometer is performing opti-
mally each day and that its performance is the same from day to day.
1. Select machine settings that are optimal for fluorochrome-labeled,
whole-blood specimens.
2. Use microbeads or other stable standardization material to place the
scatter and fluorescence peaks in the same scatter and fluorescence
channels each day. Adjust the flow cytometer as needed.
3. Maintain records of all daily standardizations. Monitor these to identify
any changes in flow cytometer performance.
4. Retain machine standardization settings for the remaining quality con-
trol procedures (sensitivity and color compensation) and for reading the
specimens.
C. Determine fluorescence resolution daily. The flow cytometer must differen-
tiate between the dim peak and autofluorescence in each fluorescence
channel.
1. Evaluate standardization/calibration material or cells that have low-level
fluorescence that can be separated from autofluorescence (e.g., mi-
crobeads with low-level and negative fluorescence or CD56-labeled
lymphocyte preparation).
2. Establish a minimal acceptable distance between peaks, monitor this dif-
ference, and correct any daily deviations.
D. Compensate for spectral overlap daily. This step corrects the spectral over-
lap of one fluorochrome into the fluorescence spectrum of another.
12 MMWR January 10, 1997
1. Use either microbead or cellular compensation material containing three
populations for two-color immunofluorescence (no fluorescence, PE
fluorescence only, and FITC fluorescence only), four populations for
three-color immunofluorescence (the three above plus a population that
is positive for only the third color), or five populations for four-color (the
four above plus a population that is positive for only the fourth color).
2. Analyze this material and adjust the electronic compensation circuits on
the flow cytometer to place the fluorescent populations in their respec-
tive fluorescence quadrants with no overlap into the double-positive
quadrant (Figure 1). If three fluorochromes are used, compensation must
be carried out in an appropriate sequence: FITC, PE, and the third color,
respectively (64 ). For four-color monoclonal antibody panels, follow the
flow cytometer manufacturer’s instructions for four fluorochromes.
Avoid over-compensation.
3. If standardization or calibration particles (microbeads) have been used to
set compensation, confirm proper calibration by using lymphocytes
labeled with FITC- and PE-labeled monoclonal antibodies (and a third-
color– or fourth-color–labeled monoclonal antibody for three-color or
four-color panels) that recognize separate cell populations but do not
overlap. These populations should have the brightest expected signals.
Note: If a dimmer-than-expected signal is used to set compensation,
suboptimal compensation for the brightest signal can result.
4. Reset compensation when photomultiplier tube voltages or optical fil-
ters are changed.
E. Repeat all four instrument quality control procedures whenever instrument
problems occur or if the instrument is serviced during the day.
F. Maintain instrument quality-control logs, and monitor them continually for
changes in any of the parameters. In the logs, record instrument settings,
peak channels, and coefficient of variation (CV) values for optical alignment,
standardization, fluorescence resolution, and spectral compensation. Re-
establish fluorescence levels for each quality-control procedure when lot
numbers of beads are changed.
IX. Sample Analyses
A. For the two-color immunophenotyping panel using a light-scatter gate,
analyze the sample tubes of each patient’s specimen in the following order:
1) The tube containing CD45 and CD14 (gating reagent): read this tube first
so that gates can be set around the lymphocyte cluster; 2) Isotype control:
set cursors for differentiating positive and negative populations so that
≤2% of the cells are positive; and 3) Remaining tubes in the panel.
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1. Count at least 2,500 gated lymphocytes in each sample. This number en-
sures with 95% confidence that the result is ≤2% standard deviation
(SD) of the “true’’ value (binomial sampling). Note: This model assumes
that variability determined from preparing and analyzing replicates is
≤2% SD. Each laboratory must determine the level of variability by pre-
paring and analyzing at least eight replicates of the last four tubes in the
recommended panel. Measure variability when first validating the meth-
odology used and again when methodologic changes are made.
2. Examine light-scattering patterns on each sample tube. Determine
whether lysis or sample preparation, which can affect light scattering, is
the same in each sample tube of a patient’s specimen. Deviation in a
particular tube usually indicates sample preparation error, and the tube
should be repeated (i.e., a new aliquot of blood should be stained and
lysed).
*A dot plot analysis of a specimen labeled with fluorescein isothiocyanate (FITC)-CD3 (horizontal
axis, green fluorescence) and phycoerythrin (PE)-CD8 (vertical axis, orange fluorescence)
demonstrates undercompensation (Panel A), proper compensation (Panel B), and overcom-
pensation (Panel C). Imaginary lines intersecting the peaks of green-only or orange-only
fluorescence and the negative control should be parallel to each axis (example, Panel D). Note
that this combination of antibodies (from the suggested monoclonal antibody panel) gives the
brightest signals for each fluorochrome and may be used for verifying spectral compensation.
FIGURE 1. Determination of appropriate compensation for spectral overlap*
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B. For three- or four-color monoclonal antibody panels using a CD45/side
scatter gate, determine the lymphocyte population based on bright CD45
fluorescence and low side scattering properties. Draw a gate on this popula-
tion and analyze the cell populations using this gate (65 ).
X. Data Analysis
A. Light-scatter gate (for two-color panels).
1. Reading from the sample tube containing CD45 and CD14, draw lympho-
cyte gates using forward and side light-scattering patterns and fluor-
escence staining.
a. When using CD45 and CD14 and light-scattering patterns for drawing
lymphocyte gates, define populations on the following basis:
• Lymphocytes stain brightly with CD45 and are negative for CD14.
• Monocytes and granulocytes have greater forward and side light-
scattering properties than lymphocytes.
• Monocytes are positive for CD14 and have intermediate to high
intensity for CD45.
• Granulocytes are dimly positive for CD14 and show less intense
staining with CD45.
• Debris, red cells, and platelets show lower forward scattering than
lymphocytes and do not stain specifically with CD45 or CD14.
b. Using the above characteristics, draw a light-scattering gate around
the lymphocyte population (66 ). Note: Other methods for drawing a
lymphocyte gate must accurately identify lymphocytes and account
for non-lymphocyte contamination of the gate.
2. Verify the lymphocyte gate by determining the recovery of lymphocytes
within the gate and the lymphocyte purity of the gate.
a. Definitions
• The lymphocyte recovery (previously referred to as the proportion
of lymphocytes within the gate) is the percentage of lymphocytes in
the sample that are within the gate.
• The lymphocyte purity of the gate is the percentage of cells within
the gate that are lymphocytes. The remainder may be monocytes,
granulocytes, red cells, platelets, and debris.
b. Optimally, the lymphocyte recovery should be ≥95%.
c. Optimally, the lymphocyte purity of the gate should be ≥90%.
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d. Optimal gates include as many lymphocytes and as few contaminants
as possible.
e. Lymphocyte recovery within the gate using CD45 and CD14 can be
determined by two different methods: light-scatter gating and fluores-
cence gating (Figures 2 and 3). Note: The number of lymphocytes
identified will be the same whether determined by light-scatter gating
or by fluorescence gating.
• Lymphocyte recovery determined by light-scatter gating is done as
follows: first, identify the lymphocytes by setting a relatively large
light-scatter gate (Figure 2, Panel A), then set an analysis region
around CD45 and CD14 lymphocyte reactivity (bright CD45-positive,
negative for CD14) (Figure 2, Panel B). Determine the number of cells
that meet both criteria (total number of lymphocytes). Set a smaller
lymphocyte light-scatter gate that will be used for analyzing the re-
maining tubes (Figure 2, Panel C). Determine the number of cells
that fall within this gate and the CD45/ CD14 analysis region (bright
CD45-positive, negative for CD14) (Figure 2, Panel D). This number
divided by the total number of lymphocytes times 100 is the lympho-
cyte recovery. The advantage of this method is that it can easily be
done on most software programs.
• Lymphocyte recovery determined by fluorescence gating is done as
follows. First, identify lymphocytes by setting a fluorescence gate
around the bright CD45-positive, CD14-negative cells (Figure 3,
Panel A), then set an analysis region around a large light-scatter re-
gion that includes lymphocytes (Figure 3, Panel B). The number of
cells that meet both criteria is the total number of lymphocytes. Set
a smaller lymphocyte light-scatter gate that will be used for analyz-
ing the remaining tubes (Figure 3, Panel C). Determine the number
of cells that fall within this gate and the CD45/CD14 analysis region
(bright CD45+, negative for CD14) (Figure 3, Panel D). This number
divided by the total number of lymphocytes times 100 is the lympho-
cyte recovery. The advantage of this method is that the light-scatter
pattern of lymphocytes can be easily determined. Note: Some in-
strument software packages automatically determine lymphocyte
recovery by fluorescence gating; others do not.
f. The lymphocyte purity of the gate is determined from the CD45 and
CD14 tube by calculating the percentage of cells in the light-scattering
gate that are bright CD45-positive and negative for CD14.
g. If the recommended recovery and purity of lymphocytes within the
gate cannot be achieved, redraw the gate. If minimum levels still can-
not be obtained, reprocess the specimen. If this fails, request another
specimen.
B. CD45 gating (for three- and four-color monoclonal panels)
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1. Identify lymphocytes as cells brightly labeled with CD45 and having low
side scattering properties.
2. Establish criteria for cluster identification based on a clear definition of
lymphocytes that does not include basophils (less bright CD45, low side
scatter) or monocytes (less bright CD45, moderate side scatter). Note:
Care must be taken to include all lymphocytes. B-cells may have slightly
less CD45 fluorescence than the T-cells (the major cluster of lympho-
cytes). NK-cells have bright CD45 fluorescence but have slightly more
side scattering properties than the majority of the lymphocytes.
*Panel A shows a large light-scatter region drawn around the lymphocytes (R1). Panel B is the
two-parameter histogram of CD45/CD14 fluorescence gated on R1. The number of cells in
quadrant 4 (bright CD45-positive, negative for CD14) is the total number of lymphocytes
(3,951 cells). Panel C is the same light-scatter histogram as Panel A except that a smaller
light-scatter gate has been drawn, which will be used for analyzing the remaining tubes from
that specimen. Panel D is the CD45/CD14 histogram from gated R2. The number of gated
lymphocytes is in quadrant 4 (3,889 cells). The total number of gated cells in R2 is 4,298. From
these numbers, the lymphocyte recovery is (3,889/3,951) x 100, or 98.4%. The lymphocyte
purity is (3,889/4,298) x 100, or 90.5%.
FIGURE 2. Light-scatter gating technique for determining lymphocyte recovery and
purity*
Vol. 46 / No. RR-2 MMWR 17
3. CD45/side scatter gates for lymphocytes are assumed to contain >95%
lymphocytes, and no further corrections need be made to the percentage
subset results (65 ).
4. Lymphocyte recovery cannot be determined without using a panel of
monoclonal antibodies that identify T-, B-, and NK-cells. Note: Validation
of a CD45/side scatter gate is recommended when beginning to use
CD45/ side scatter gates to help determine the CD45 and side scatter
characteristics of T-, B-, and NK-cells and to ensure their inclusion in the
gate.
C. Set cursors using the isotype control so that <2% of cells are positive. Note:
If an isotype control is not used, set cursors based on the tube containing
CD3 and CD4 so that the negative and positive cells in the histogram are
clearly separated. These cursors may be used for the remaining tubes. If
*Panel A shows a region (R1) drawn around the lymphocytes identified by fluorescence (bright
CD45-positive, negative for CD14). Panel B is the two-parameter light-scatter histogram gated
on R1. A relatively large light-scatter region (R2) is set around the lymphocytes. The number
of cells in this region is the total number of lymphocytes (3,846). Panel C shows the light-
scatter histogram with a smaller light-scatter gate drawn (R2), which will be used for analyzing
the remaining tubes from that specimen. Panel D is the CD45/CD14 histogram from gated R2,
Panel C. The number of gated lymphocytes is in R1 (3,771 cells). The total number of gated
cells in R2, Panel C is 4,139. From these numbers, the lymphocyte recovery is (3,771/3,846) x
100, or 98.0%. The lymphocyte purity is (3,771/4,139) x 100, or 91.1%.
FIGURE 3. Fluorescence gating technique for determining lymphocyte recovery and
purity*
18 MMWR January 10, 1997
CD16 and/or CD56 are included in a monoclonal antibody panel, an isotype
control may be needed to help identify negative cells.
D. Analyze the remaining samples with the cursors set. Note: In some
instances, the isotype-set cursors will not accurately separate positive and
negative staining for another sample tube from the same specimen. In such
cases, the cursors can be moved on that sample to more accurately separate
these populations. The cursors should not be moved when fluorescence dis-
tributions are continuous with no clear demarcation between positively and
negatively labeled cells.
E. Analyze each patient or control specimen with lymphocyte gates and cur-
sors for positivity set for that particular patient or control.
F. When spectral compensation of a particular specimen appears to be inap-
propriate because FITC-labeled cells have been dragged into the PE-positive
quadrant or vice-versa (when compensation on all other specimens is ap-
propriate) (67 ), repeat the sample preparation, prewashing the specimen
with phosphate-buffered saline (PBS) (pH 7.2) to remove plasma before
monoclonal antibodies are added.
G. Include the following analytic reliability checks, when available:
1. Optimally, at least 95% lymphocyte recovery (proportion of lymphocytes
within the lymphocyte gate) should be achieved. Minimally, at least 90%
lymphocyte recovery should be achieved. Note: These determinations
can only be made when using either CD14 and CD45 to validate the gate
or when using T, B, and NK reagents to validate a gate.
2. Optimally, ≥90% lymphocyte purity should be observed within the lym-
phocyte gate. Minimally, ≥85% purity should be observed within the
gate.
3. Optimally, the sum of the percentage of CD3+CD4+ and CD3+CD8+ cells
should equal the total percentage of CD3+ cells within ±5%, with a maxi-
mum variability of ≤10%. Note: In specimens containing a considerable
number of T γδ cells (68,69 ), this reliability check may exceed the maxi-
mum variability.
4. Optimally, the sum of the percentage of CD3+ (T-cells), CD19+ (B-cells),
and CD3-(CD16 and/or CD56)+ (NK-cells) should equal the purity of lym-
phocytes in the gate ±5% (61 ), with a maximum variability of ≤10%. If the
data are corrected for lymphocyte purity (see XII.B.), the sum should ide-
ally equal 95%–105% (or at a minimum 90%–110%).
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XI. Data Storage
A. If possible, store list-mode data on all specimens analyzed. This allows for
reanalysis of the raw data, including redrawing of gates. At a minimum, re-
tain hard copies of the lymphocyte gate and correlated dual histogram data
of the fluorescence of each sample.
B. Retain all primary files, worksheets, and report forms for 2 years or as re-
quired by state or local regulation, whichever is longer. Data can be stored
electronically. Disposal after the retention period is at the discretion of the
laboratory director.
XII. Data Reporting
A. Report all data in terms of CD designation, with a short description of what
that designation means. Note: CD4+ T-cells are T-helper cells. The correct
cells to report for this value are those that are positive for both CD3 and CD4.
Similarly, CD8+ T-cells are T-suppressor/cytotoxic cells and are positive for
both CD3 and CD8. Do not include other cell types (non-T-cells) in CD4 and
CD8 T-cell determinations.
B. If using light-scatter gates, report data as a percentage of the total lympho-
cytes and correct for the lymphocyte purity of the gate. For example, if the
lymphocyte purity is 94% and the CD3 value is 70%, correct the CD3 value
by dividing 0.70 by 0.94 and then multiply the result by 100 to result in a
T-lymphocyte value of 74%.
C. Report absolute lymphocyte subset values when an automated complete
blood cell (CBC) count (WBC and differential) has been performed from
blood drawn at the same time as that for immunophenotyping.
1. Calculate the absolute values by multiplying the lymphocyte subset
percentage (from flow cytometry data) by the absolute number of lym-
phocytes (from WBC and differential). Note: The hematology laboratory
providing the CBC (WBC and differential) must perform satisfactorily in a
hematology proficiency testing program approved by the Health Care
Finance Administration (HCFA) as meeting the requirements of the Clini-
cal Laboratory Improvement Amendments of 1988 (CLIA ‘88).*
2. Report both percentages and absolute counts when these are available.
Note: If absolute counts are determined directly on the flow cytometer,
report these results.
*42 CFR part 493 § 493.801–493.865.
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D. Report data from all relevant monoclonal antibody combinations with corre-
sponding reference limits of expected normal values (e.g., CD4+ T-cell
percentage and absolute number of CD4+ T-cells). Reference limits for im-
munophenotyping test results must be determined for each laboratory (29 ).
Separate reference ranges must be established for adults and children, and
the appropriate ranges must be used for patient specimens.
XIII.Quality Assurance
A. Assure the overall quality of the laboratory’s CD4+ T-cell testing by monitor-
ing and evaluating the effectiveness of the laboratory policies and pro-
cedures for the preanalytic, analytic, and postanalytic testing phases. The
practices and processes to be monitored and evaluated include:
1. Methods for collecting, handling, transporting, identifying, processing,
and storing specimens.
2. Information provided on test request and results report forms.
3. Instrument performance, quality-control protocols, and maintenance.
4. Reagent quality-control protocols.
5. Process for reviewing and reporting results.
6. Employee training and education, which should consist of:
a. Basic training by flow cytometer manufacturers and additional
training in hands-on workshops for flow cytometer operators and
supervisors.
b. Education of laboratory directors in flow cytometric immunopheno-
typing through workshops and other programs.
c. Continuing education in new developments for all flow cytometric
immunophenotyping personnel through attendance at meetings and
workshops.
d. Adherence to federal and state regulations for training and education.
7. Assurance of satisfactory performance. Laboratories must successfully
participate in a performance evaluation program. When proficiency test-
ing programs are approved by HCFA as meeting the requirements of
CLIA ’88 (none are currently approved for CD4+ T-cell testing), laborato-
ries must satisfactorily participate.
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8. Review and revision (as necessary, or at established intervals) of the
laboratory’s policies and procedures to assure adherence to the quality
assurance program. All staff involved in the testing should be informed
of any problems identified during the quality assurance review, and the
corrective actions should be taken to prevent recurrences.
B. Document all quality assurance activities.
LABORATORY VALIDATION OF SINGLE-PLATFORM CD4+
T-CELL METHODS
When performing method-validation studies on the new single-platform methods
for enumerating CD4+ T-cell populations, laboratorians must consider that these as-
says may determine the absolute CD4+ count using methodologies that are very
different from multi-platform techniques. In most clinical settings, multi-platform
methods do not perform at the level of a gold standard. Still, the single-platform meth-
ods must be compared with accepted methods or testing procedures. When no
optimal standard exists and bias is present, the amount of error contributed by each
method cannot be determined. Therefore, if results yielded from a single-platform
method are significantly different from those obtained using a multi-platform method,
the new method is not necessarily in error. Conducting a large-scale study correlating
results from single-platform methods with clinical disease data to establish new medi-
cal decision points may be the only surrogate for comparison with a gold standard.
Laboratories should not adopt methods that yield results significantly different from
multi-platform methods until these studies can be performed, published, and ac-
cepted by the scientific and medical communities.
Traditional method comparison tools may be used for validation of single-platform
methods that compare favorably with multi-platform methods. Single-platform meth-
ods, as the name implies, derive the absolute CD4+ T-cell counts from a single
measurement and therefore have the potential to yield a less variable (although not
necessarily more accurate) analysis than multi-platform methods, which utilize a com-
bination of hematology and flow cytometry measurements. Laboratorians should
utilize statistical tools that provide useful information about these new methodologies
but that do not presume that either the comparative or test method is definitive. Linear
least squares regression analysis must be conducted based on the assumption that no
error exists in the comparative method, and regression-type scatter plots provide in-
adequate resolution when the errors are small in comparison to the analytical range
(70,71 ). The bias scatterplot may provide laboratorians with a more useful tool for
determining bias (Figure 4). These simple, high resolution graphs plot the difference
in the individual measurements of each method (X test method - X comparative method)
against those by one of the methods (X comparative method) (70 ). Such graphs provide
an easy means of determining if bias is present and distinguishing if bias is system-
atic, proportional, or random/non-constant. The laboratorian may visually determine
the significance of these differences over the entire range of values, and when suffi-
cient values are plotted, outliers and/or samples containing interfering substances
can be identified. The laboratorian may then divide the data into ranges relevant to
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medical decisions and calculate the systematic error (mean of the bias), the random
error (standard deviation of the bias), and total error (the greatest absolute 95% error
limit of the systematic error twice the random error) to gain insight into analytical
performance at the specified decision points (70,71 ). Several detailed guidelines and
texts can provide laboratorians with additional information regarding quality goals,
method evaluation, estimation of bias, and bias scatter plots (70–76 ). Once a new
method is accepted and implemented, the laboratory should continue to monitor the
correlation between the results and the patient’s clinical disease data to ensure that no
problems have gone undetected by the relatively few samples typically tested during
method evaluations.
DISCUSSION
On the basis of the reported number of tests performed annually by laboratories
participating in CDC’s Model Performance Evaluation Program for T-lymphocyte im-
munophenotyping in 1995, more than 1.6 million CD4+ T-cell measurements are
performed yearly by the approximately 600 testing laboratories in the United States
(77 ). Most of these measurements are made by using multi-platform flow cytometric
methods, although new single-platform methods (both flow cytometric and others)
are available (78–85 ). Recommendations concerning CD4+ T-lymphocyte immuno-
phenotyping have focused on the more complex multi-platform process of measuring
CD4+ T-cells. The recommendations for testing have increasingly been adopted (86 ),
and as a result, laboratorians have reported improved testing practices (86,87 ). Test-
ing outcomes associated with following the recommendations include a) increased
confidence in results, b) more reproducible results, c) increased ability to resolve dis-













































































































FIGURE 4. Simplified examples of bias scatter plots
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testing, e) decreased proportion of specimens requiring reanalysis, and f) decreased
incidents that could pose biohazard risks (86 ).
Although data suggest that guidelines for CD4+ T-cell lymphocyte immunopheno-
typing have improved many laboratory practices, developing guidelines that address
every aspect of CD4+ T-cell testing (including some laboratory-specific practices) is
not possible. Moreover, measuring the outcomes associated with the adoption of
these guidelines is inherently difficult. First, the guidelines lack evaluation protocols
that can adequately account for the interactions among recommendations. No weight
of importance has been assigned for the individual recommendations that address
unique steps in the testing process; hence, the consequences of incompletely follow-
ing the entire set of recommendations are uncertain. Second, because published data
were not available as the basis for every guideline, some recommendations are based
on experience and expert opinion. Recommendations made on this basis, in the ab-
sence of data, may be biased and inaccurate. Finally, variations in testing practices
and interactions among the practices (e.g., how specimens are obtained and proc-
essed, laboratory personnel credentials and experience, testing methods used,
test-result reporting practices, and compliance with other voluntary standards and
laboratory regulations) complicate both development of guidelines that will fit
every laboratory’s unique circumstances and measurement of the value of guideline
implementation.
When the first CDC recommendations for laboratory performance of CD4+ T-cell
testing were developed, the guidelines were written so as not to impede development
of new technology or investigations into better ways to assess the status of the
immune system in HIV-infected persons. Presentations at the second national confer-
ence in Atlanta indicated that although CD4+ T-cell testing by multi-platform flow
cytometry is still being performed by most laboratories, other single-platform meth-
ods are being implemented. In addition, alternative T-cell phenotypic markers are
being investigated as prognostic indicators or markers of treatment efficacy, alone
and in combination with other markers (88 ).
Participants at the second national conference emphasized the need for monitor-
ing the intralaboratory and interlaboratory accuracy, precision, and reliability of
current and new procedures. Decisions about implementing and modifying proce-
dures should be based on performance data collected to assess the extent to which
the quality goals established by providers and users of laboratory testing services are
achieved (76 ). In testing areas where no absolute gold standards exist (e.g., CD4+
T-cell enumeration), method validation and verification processes are even more criti-
cal. Laboratorians should continue to rely on as many sources of information and data
as possible to help in their decision processes. Factors that have contributed to im-
proved testing practices and that are important resources for laboratorians include
regulatory* and voluntary laboratory standards (29,31,32,34,89 ); manufacturer’s
recommendations; proficiency testing and performance evaluation program data;
information shared at scientific conferences, meetings, and training sessions; and
publications in scientific literature.
*42 CFR part 493 § 493.801–493.865.
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APPENDIX. Effects of medications and other biologic factors on immunophenotyping
results
Causative agent Effect Result
Zidovudine (AZT) Increased granuloctye fragility; Poor light-scattering (increased
  red blood cells (RBCs) less
susceptible to lysing reagents








Corticosteroids Decreased CD4+ T-cell levels Decreased CD4+ T-cell
percentage and absolute
number
Strenuous exercise Decreased lymphocyte counts Lower absolute lymphocyte
subset values
Diurnal variation Changes in absolute lympho-
cyte counts
Variable absolute lymphocyte
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